Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 521 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Blood Test Accurately Detects Early-Stage Pancreatic Cancer May 10, 2024 WHO’s plans to create a ‘cervical cancer-free future’ April 19, 2021 EMA Recommends Extending Indications for Trastuzumab Deruxtecan to Include Treatment of... October 12, 2023 Breast Cancer Patient Who Continued Teaching Throughout Her Treatment Wins Teacher... February 9, 2021 Load more HOT NEWS Volunteering with Pride: Brett’s award-winning involvement with Cancer Research UK A Subset of Patients with NSCLC Respond Poorly to the COVID-19... ESMO Asia Congress 2022, 2-4 December 2022 Health inequalities: Why do people smoke if they know it’s bad...
